How to optimize HCV therapy in genotype 4 patients

Esmat, Gamal; Kassas, Mohamed El; Hassany, Mohamed; Gamil, Mohamed; Raziky, Maissa El

doi:10.1111/liv.12059

Cited by 14 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 17 While this may be explained by confounding factors such as patient body mass index (BMI), it has been a consistent finding across studies. 18 …”

Section: Historical Success With Dual Therapymentioning

confidence: 99%

Management of hepatitis C genotype 4 in the directly acting antivirals era

Hathorn

Elsharkawy

2016

BMJ Open Gastroenterol

View full text Add to dashboard Cite

Genotype 4 chronic hepatitis C (G4 HCV) accounts for 13% of worldwide HCV infections; with 10 million people infected with the virus across the world. Up to the end of 2013, the only treatment option for G4 HCV was treatment with pegylated interferon and ribavirin for 24–48 weeks. Since late 2013, treatment of G4 HCV has been transformed by the licensing of many directly acting antiviral agents (DAA). It is an exciting time to be involved in the management of HCV generally and G4 particularly. Interferon-free DAA regimens are now a reality for G4 HCV. This review will highlight these developments and discuss the data behind the use of these drugs. It will also highlight future regimens that are likely to be available over the coming years.

show abstract

“… 17 While this may be explained by confounding factors such as patient body mass index (BMI), it has been a consistent finding across studies. 18 …”

Section: Historical Success With Dual Therapymentioning

confidence: 99%

Management of hepatitis C genotype 4 in the directly acting antivirals era

Hathorn

Elsharkawy

2016

BMJ Open Gastroenterol

View full text Add to dashboard Cite

show abstract

“…10 In 2015, more than 6% of the Egyptian population has been tested HCV antibody positive and the rate of infection increases with age reaching 27.6% in those aged (55-59 years). 11,12 As a response to this epidemic, and because of the exclusive prevalence of genotype 4 with its hard to treat nature with interferon-based therapies, 13,14 Egypt launched a large program for controlling HCV pandemic that relied on a wide network of specialized viral hepatitis treatment centers covering the country to secure access to antiviral medications. 15,16 Through this program, Egypt was able to treat more than one million patients with high success rates.…”

Section: Introductionmentioning

confidence: 99%

High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results

Kassas

Alboraie

Omar

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Introduction and Aims: Treatment of hepatitis C virus (HCV) genotype 4 patient with fixed dose combination of ombitasvir-paritaprevir-ritonavir plus ribavirin (OBV/rPTV/RBV) has been proven efficacy and safety in many clinical trials. The current study reports the efficacy and safety of OBV/rPTV/RBV (for treatmentnaïve), and OBV/rPTV/RBV/sofosbuvir (SOF) (for treatment-experienced), in chronic HCV genotype 4 patients in real life settings.Methods: Prospective cohort study including all adult chronic HCV genotype 4 patients who were scheduled to receive OBV/rPTV/RBV ± SOF for 12 or 24 weeks in New Cairo Viral Hepatitis Treatment Center. The primary efficacy endpoint was a virologic response at posttreatment week 12 (SVR12). Changes in hematological parameters, liver biochemical profile and fibrosis-4 index (FIB-4), as well as clinical and laboratory adverse events (AEs) across follow up visits (week 4, end of treatment [EOT], and SVR12), were recorded.Results: Our study included 325 patients (age; 47.63 ± 12.63 years, 55.38% [n = 180] men). Most of the included patients (89.85%, n = 292) were treatment naïve and only 7% (n = 23) had liver cirrhosis. Overall, SVR12 was attained by 98.44% (316 of 321) of the patients; 97.15% (307 of 316) of patients who received 12 weeks of OBV/rPTV/ RBV ± SOF and 100% (9 of 9) of patients who received 24 weeks of OBV/rPTV/RBV as assessed by modified intention to treat analysis. There was a significant improvement of baseline alanine aminotransferase, aspartate aminotransferase, hemoglobin, FIB-4 at SVR12 (P < 0.05). The most common reported AEs were anemia (n = 106), fatigue (n = 41) and elevated indirect bilirubin (n = 37). Conclusion:OBV/rPTV/RBV (±SOF) is a highly effective therapy for chronic HCV patients in real life settings.

show abstract

“…Egypt is one of the countries with a high HCV burden; the percentage of HCV antibody positivity is 4.61 % of in Egyptian general population (Abdel-Moneim et al, 2018a). Egyptian National Committee for Control of Viral Hepatitis (NCCVH) implemented a model of care for HCV, aiming at providing a framework for control of HCV infection, reducing the prevalence and burden of HCV, and targeting disease elimination by 2030 (Gomaa et al, 2017;Gore et al, 2017), which is also a major health target adopted by World Health Organization (WHO) (Esmat et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: A multicenter study

Kassas

Alboraie

Badry

et al. 2020

International Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

The current study aimed to evaluate the efficacy of different DAAs regimens in the treatment of chronic hepatitis C (CHC) Egyptian patients who failed to achieve SVR after their treatment with SOF-based regimens. Methods: This was a retrospective observational multicenter study that included CHC patients that failed to achieve cure on SOF-based regimens who were re-treated using different DAAs regimen and were allocated according to national guidelines for the treatment of hepatitis C. Primary outcome was to assess the SVR12 rate among prior non-responders after retreatment with a second course of DAAs. Results: Our study included 172 patients who failed to achieve SVR after treatment with SOF-based treatment regimen [age: 51.2 AE 11.3, 58.7% men]. Included patients were retreated using SOF/DCV/RBV, SOF/ r/PAR /OMB /RBV, SOF/DCV/SIM, SOF/LDV AE RBV or SIM/SOF. SVR12 was successfully attained in 95.35% (164/172) of the included non-responders. Conclusion:The current multicenter study proved the efficacy of various DAAs regimens issued by the National Committee for Control of Viral Hepatitis for retreatment of relapsed CHC Egyptian patients.

show abstract

How to optimize HCV therapy in genotype 4 patients

Cited by 14 publications

References 41 publications

Management of hepatitis C genotype 4 in the directly acting antivirals era

Management of hepatitis C genotype 4 in the directly acting antivirals era

High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results

Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: A multicenter study

Contact Info

Product

Resources

About